Faculty Opinions recommendation of Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.

2013 ◽  
Author(s):  
Sabine Tejpar ◽  
Loredana Vecchione
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase 2 ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Phase 2 Study ◽  
Randomized Phase 2

scholarly journals Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study

Cancer ◽  
2013 ◽  
Vol 119 (14) ◽  
pp. 2555-2563 ◽  
Author(s):  
Jeffrey R. Infante ◽  
Tony R. Reid ◽  
Allen L. Cohn ◽  
William J. Edenfield ◽  
Terrence P. Cescon ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase 2 ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Phase 2 Study ◽  
Randomized Phase 2

scholarly journals A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer

Cancer ◽  
2011 ◽  
Vol 118 (17) ◽  
pp. 4132-4138 ◽  
Author(s):  
Robert A. Wolff ◽  
Martin Fuchs ◽  
Maria Di Bartolomeo ◽  
Anwar M. Hossain ◽  
Clemens Stoffregen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase 2 ◽  
First Line ◽  
Double Blind ◽  
First Line Therapy ◽  
Line Therapy ◽  
Phase 2 Study

scholarly journals R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

2021 ◽  
Author(s):  
Juan‐Manuel Sancho ◽  
Rubén Fernández‐Alvarez ◽  
Francisco Gual‐Capllonch ◽  
Esther González‐García ◽  
Carlos Grande ◽  
...  
Keyword(s):  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
First Line ◽  
First Line Therapy ◽  
Large B Cell Lymphoma ◽  
Line Therapy ◽  
Phase 2 Study ◽  
Randomized Phase 2 ◽  
Large B Cell

scholarly journals Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G

2016 ◽  
Vol 27 ◽  
pp. vi582 ◽  
Author(s):  
C. Langer ◽  
S.M. Gaddgeel ◽  
H. Borghaei ◽  
V.A. Papadimitrakopoulou ◽  
A. Patnaik ◽  
...  
Keyword(s):  
Advanced Nsclc ◽  
Phase 2 ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Phase 2 Study ◽  
Randomized Phase 2
Sign in / Sign up

Export Citation Format

Share Document